SIREN : 478202419
H2 PHARMA is a French company founded 21 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in BOIS-D'ARCY (78390), this company of category PME shows in 2019 a revenue of 30.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2019 | 2017 |
|---|---|---|
| Revenue | 30 489 268 € | 24 230 521 € |
| Net income | 2 632 299 € | 1 862 572 € |
| EBITDA | 4 122 588 € | 2 621 483 € |
| Net margin | 8.6% | 7.7% |
In 2019, H2 PHARMA achieves revenue of 30.5 M€. Vs 2017, growth of +26% (24.2 M€ -> 30.5 M€). After deducting consumption (16.8 M€), gross margin stands at 13.7 M€, i.e. a rate of 45%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 4.1 M€, representing 13.5% of revenue. Positive scissor effect: EBITDA margin improves by +2.7 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.6 M€, i.e. 8.6% of revenue. This profit can be retained or distributed to shareholders.
30 489 268 €
13 731 225 €
4 122 588 €
3 799 308 €
2 632 299 €
13.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 9.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.193%
66.85%
9.893%
0.022
21.9%
In 2019, the debt ratio of H2 PHARMA (0.19) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2019, the financial autonomy of H2 PHARMA (66.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2019, the repayment capacity of H2 PHARMA (0.02) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 144.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.2x. Danger: operating income does not cover interest charges, unsustainable situation.
144.546
0.212
In 2019, the liquidity ratio of H2 PHARMA (144.55) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2019, the interest coverage of H2 PHARMA (0.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 72 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 215 days. Excellent situation: suppliers finance 143 days of the operating cycle (retail model). Inventory turnover is 44 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 218 days of revenue, i.e. 18.4 M€ to permanently finance.
18 429 543 €
72 j
215 j
44 j
218 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 525 194€ to 1 614 242€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare H2 PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of H2 PHARMA in 2019 is 30.5 M€.
Yes, H2 PHARMA generated a net profit of 2.6 M€ in 2019.
The headquarters of H2 PHARMA is located in BOIS-D'ARCY (78390), in the department Yvelines.
The tax return of H2 PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
H2 PHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.